Literature DB >> 7114542

Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults.

D M Fisher, C O'Keeffe, D R Stanski, R Cronnelly, R D Miller, G A Gregory.   

Abstract

The pharmacokinetics and pharmacodynamics of d-tubocurarine (dTc) were determined in neonates (0-2 months, n = 7), infants (2-12 months, n = 7), children (1-12 years, n = 9), and adults (12-30 years, n = 8) during 70% nitrous oxide, 0.58 MAC halothane anesthesia. dTc was administered by infusion, while blood for determination of plasma dTc concentrations was obtained, and the EMG of the adductor pollicis recorded. The plasma dTc concentration at which 50% depression of EMG twitch height occurs (Cpss(50)) was 0.18 +/- 0.09 micrograms/ml in neonates, and 0.27 +/- 0.06 micrograms/ml in infants, both significantly lower than the values of 0.42 +/- 0.14 and 0.53 +/- 0.14 micrograms/ml for children and adults, respectively. The steady-state distribution volume (Vdss) was 0.74 +/- 0.33 l/kg in neonates, significantly greater than the values of 0.52 +/- 0.22, 0.41 +/- 0.12, and 0.30 +/- 0.10 l/kg in infants, children, and adults, respectively. The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively. Plasma clearance did not differ with age. We also determined D50, the product of Vdss and Cpss(50). D50, the quantity of drug present at steady-state to produce 50% paralysis, did not differ between groups. The authors conclude that during comparable nitrous oxide-halothane anesthesia, neonates and infants have an increased sensitivity to dTc, as determined by CPss(50). However, because of the larger Vdss in younger patients, dose size should not differ with age. In addition, because of the longer t beta 1/2 in neonates, second and subsequent doses should be required at less frequent intervals.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7114542     DOI: 10.1097/00000542-198209000-00009

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  21 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 3.  The role of population PK-PD modelling in paediatric clinical research.

Authors:  Roosmarijn F W De Cock; Chiara Piana; Elke H J Krekels; Meindert Danhof; Karel Allegaert; Catherijne A J Knibbe
Journal:  Eur J Clin Pharmacol       Date:  2010-03-26       Impact factor: 2.953

Review 4.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

5.  Current considerations in neonatal anaesthesia.

Authors:  R Waugh; G G Johnson
Journal:  Can Anaesth Soc J       Date:  1984-11

Review 6.  Developmental pharmacokinetics in pediatric populations.

Authors:  Hong Lu; Sara Rosenbaum
Journal:  J Pediatr Pharmacol Ther       Date:  2014 Oct-Dec

7.  Neuromuscular blockade in infants following intramuscular succinylcholine in two or five per cent concentration.

Authors:  G A Sutherland; J C Bevan; D R Bevan
Journal:  Can Anaesth Soc J       Date:  1983-07

8.  Vecuronium in renal failure.

Authors:  D R Bevan; F Donati; H Gyasi; A Williams
Journal:  Can Anaesth Soc J       Date:  1984-09

9.  Accelerated onset and delayed recovery of d-tubocurarine blockade with pancuronium in infants and children.

Authors:  C E Smith; M Baxter; J C Bevan; F Donati; D R Bevan
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

10.  Fundamentals of infant anaesthesia.

Authors:  C F Ward
Journal:  Can Anaesth Soc J       Date:  1984-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.